Los Angeles Capital Management LLC Invests $965,000 in Repligen Co. (NASDAQ:RGEN)

Los Angeles Capital Management LLC acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 5,368 shares of the biotechnology company's stock, valued at approximately $965,000.

Several other institutional investors also recently bought and sold shares of the business. Signaturefd LLC boosted its position in Repligen by 44.1% during the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 86 shares in the last quarter. Milestone Investment Advisors LLC purchased a new position in Repligen in the third quarter valued at about $61,000. Headlands Technologies LLC bought a new position in Repligen in the third quarter worth about $75,000. Nisa Investment Advisors LLC raised its holdings in Repligen by 67.6% in the third quarter. Nisa Investment Advisors LLC now owns 533 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 215 shares in the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Repligen during the third quarter valued at about $95,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, VP Ralf Kuriyel sold 3,517 shares of the company's stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the transaction, the vice president now owns 24,260 shares of the company's stock, valued at approximately $4,699,889.80. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, VP Ralf Kuriyel sold 3,517 shares of the firm's stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO James Bylund sold 4,373 shares of the business's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the sale, the chief operating officer now owns 14,135 shares in the company, valued at approximately $2,799,860.80. The disclosure for this sale can be found here. Insiders sold a total of 25,597 shares of company stock valued at $5,039,532 over the last quarter. 1.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on RGEN shares. Stifel Nicolaus boosted their price objective on shares of Repligen from $165.00 to $207.00 and gave the stock a "buy" rating in a research note on Thursday, February 22nd. KeyCorp increased their price objective on Repligen from $210.00 to $220.00 and gave the company an "overweight" rating in a report on Thursday, February 15th. Finally, JPMorgan Chase & Co. dropped their target price on Repligen from $230.00 to $200.00 and set an "overweight" rating on the stock in a research note on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $197.75.

Repligen Trading Up 1.2 %

Repligen stock traded up $1.92 during trading on Friday, reaching $166.81. 337,446 shares of the company were exchanged, compared to its average volume of 534,117. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13. The company has a market capitalization of $9.32 billion, a P/E ratio of 659.56, a PEG ratio of 5.58 and a beta of 1.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24. The stock's 50 day simple moving average is $178.64 and its two-hundred day simple moving average is $174.49.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.01). The company had revenue of $151.31 million for the quarter, compared to analysts' expectations of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business's quarterly revenue was down 17.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.64 EPS. On average, equities research analysts expect that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.